Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Penumbra (DE:0P8)
FRANKFURT:0P8
Holding DE:0P8?
Track your performance easily
0P8 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€97.86 - €254.00
Previous Close€176.55
Volume0.00
Average Volume (3M)11.00
Market Cap
€6.90B
Enterprise Value€6.80B
Total Cash (Recent Filing)$339.69M
Total Debt (Recent Filing)$228.82M
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Oct 30, 2024EPS Estimate
€0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding38,843,936
10 Day Avg. Volume0
30 Day Avg. Volume11
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)5.92
Price to Sales (P/S)6.68
Price to Cash Flow (P/CF)83.70
P/FCF Ratio102.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.00
Enterprise Value/Gross Profit9.96
Enterprise Value/Ebitda-143.52
Forecast
1Y Price Target
€181.40Price Target Upside2.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
Penumbra News
PremiumThe Fly
Penumbra rises 12.2%Bulls Say, Bears Say
Bulls Say
Financial PerformancePEN's positive cash flow model, outsized growth, and margin profile are significant points of differentiation not just compared to peers, but across small to mid-cap companies.
Market Leadership And InnovationPEN is the global leader of mechanical thrombectomy, a procedure used to remove blood clots across various vascular diseases and disorders.
Product Expansion And ApprovalsPEN announced CE Mark for its Lightning Flash and Lightning Bolt, the first CAVT products to be approved outside of the US, which should contribute to improving thrombectomy performance internationally.
Bears Say
CompetitionWith competition seemingly intensifying along with unanticipated idiosyncratic headwinds, visibility into the underlying performance of the business has become obfuscated.
Market VisibilityLack of clear visibility on the current composition of revenue between the different commercial markets included in PEN's newly reported Thrombectomy segment has weighed on the stock.
Revenue GuidanceManagement lowered FY24 revenue guidance by $60M at the midpoint following the Q2 print.
---
Options Prices
Currently, No data available
---
Ownership Overview
3.49% Insiders
43.49% Mutual Funds
0.00% Other Institutional Investors
31.96% Public Companies and
Individual Investors
0P8 FAQ
What was Penumbra’s price range in the past 12 months?
Penumbra lowest stock price was €97.86 and its highest was €254.00 in the past 12 months.
What is Penumbra’s market cap?
Currently, no data Available
When is Penumbra’s upcoming earnings report date?
Penumbra’s upcoming earnings report date is Oct 30, 2024 which is in 25 days.
How were Penumbra’s earnings last quarter?
Penumbra released its earnings results on Jul 30, 2024. The company reported €0.574 earnings per share for the quarter, beating the consensus estimate of €0.499 by €0.075.
Is Penumbra overvalued?
According to Wall Street analysts Penumbra’s price is currently Undervalued.
Does Penumbra pay dividends?
Penumbra does not currently pay dividends.
What is Penumbra’s EPS estimate?
Penumbra’s EPS estimate is €0.62.
How many shares outstanding does Penumbra have?
Penumbra has 38,843,937 shares outstanding.
What happened to Penumbra’s price movement after its last earnings report?
Penumbra reported an EPS of €0.574 in its last earnings report, beating expectations of €0.499. Following the earnings report the stock price went down -3.493%.
Which hedge fund is a major shareholder of Penumbra?
Among the largest hedge funds holding Penumbra’s share is PRIMECAP Management Co. It holds Penumbra’s shares valued at 7M.
---
Penumbra Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€181.40 (2.75% Upside)
€181.40 (2.75% Upside)
Blogger Sentiment
Bullish
DE:0P8 Sentiment 100%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.71%
12-Months-Change
Fundamentals
Return on Equity
1.28%
Trailing 12-Months
Asset Growth
7.12%
Trailing 12-Months
Company Description
Penumbra
Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers thrombectomy, embolization, access, neurosurgical tools, ruby coil system, lantern, penumbra occlusion device (POD) system, packing coil, and indigo systems products. Its target markets include interventional neuroradiologists, neurosurgeons, and interventional neurologists; and interventional radiologists, vascular surgeons, and interventional cardiologists. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004 and is headquartered in Alameda, CA.
---
0P8 Earnings Call
Q2 2024
0:00 / 0:00
---
0P8 Stock 12 Month Forecast
Average Price Target
€181.40
▲(2.75% Upside)
Technical Analysis
Penumbra
―
Axonics Modulation Technologies
―
Inspire Medical Systems
―
NovoCure
―
SI-Bone
―
Best Analysts Covering 0P8
1 Year
1 Year Success Rate
8/14 ratings generated profit
1 Year Average Return
+10.19%
assigned a buy rating 2 months ago
Copying David Rescott's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +10.19% per trade.
---